A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

NCT04729751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Familial Intrahepatic Cholestasis
Alagille Syndrome
Cholestatic Liver Disease

Interventions

DRUG: Maralixibat

Sponsor

Mirum Pharmaceuticals, Inc.